TransMedics Group Inc. (TMDX)
TMDX trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1756262/000119312526067032/0001193125-26-067032-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TMDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001756262 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | MA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $605.5M |
| Net income | $190.3M |
| Operating income | $108.6M |
| Net margin | 31.4% |
| Operating margin | 17.9% |
| Revenue growth | +37.1% |
| Cash | $488.9M |
| Total assets | $1.1B |
| P/E (computed) | 16.8× |
| P/S (computed) | 5.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $511.4M cash; operating cash flow $28.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 34,733,883 (2026-11-02); 34,174,325 a year earlier; 32,647,698 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.1M, sold $4.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $203.0M | $17.1M | $36.0M | $511.4M | $54.8M | $727.6M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $189.9M | $14.7M | $17.3M | $491.1M | $59.7M | $668.5M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $173.9M | $7.3M | $24.5M | $480.2M | $59.7M | $635.9M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $160.8M | $105.4M | $34.5M | $488.9M | $59.6M | $605.5M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $143.8M | $24.3M | $69.6M | $466.7M | $59.6M | $566.4M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $157.4M | $34.9M | $91.6M | $401.1M | $59.5M | $531.3M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $143.5M | $25.7M | -$2.9M | $310.6M | $59.4M | $488.2M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $121.6M | $6.9M | $19.7M | $337.1M | $59.4M | $441.5M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2022-08-05 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-05-07 |
Source: SEC EDGAR submissions feed, 632 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.6% |
| 1 month | +15.5% |
| 3 months | +1.9% |
| Year to date | -24.9% |
| 1 year | -20.9% |
| From 52-week high | -39.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AXGN | Axogen Inc. | $55.38 | -0.98% | $3.3B |
| LIVN | LivaNova PLC | $92.44 | +1.23% | $5.1B |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier